Latest Health News

ActivEX Limited has fully repaid its $2.3 million loan to Star Diamond Developments by transferring full ownership of its East Coast Gold and Copper subsidiary, leaving the company debt free and financially strengthened.

OzAurum Resources has secured environmental approval for Stage 1 of its Mulgabbie North Gold Project, clearing a major regulatory hurdle and accelerating its path to near-term production.

FleetPartners Group Limited has announced a $20 million on-market share buy-back, reinforcing its strong balance sheet and commitment to shareholder returns alongside its existing dividend policy.

EVE Health Group has completed R&D on multiple reformulated drug candidates targeting major sexual health and cardiovascular markets, preparing patent filings and licensing strategies to capitalise on a combined $30 billion global opportunity.

Micro-X has reached a key development milestone with the completion of its first Full Body CT laboratory test bench, securing a $1.6 million payment from US government partner ARPA-H and advancing its innovative medical imaging program.

Queste Communications Ltd reported a positive net cash flow from operating activities for February 2026, supported by a robust cash balance and stable financing arrangements. The company’s consolidated position, including its majority stake in Orion Equities, underscores its solid liquidity outlook.

OM Holdings has declared a special dividend following the sale of its 26% interest in Ntsimbintle Mining, signalling a strategic return of capital to shareholders.

Cyclopharm Limited has responded to ASX queries clarifying the material significance of its Technegas® contract with the US National Institutes of Health, while confirming robust progress in expanding its US footprint.

Island Pharmaceuticals has partnered with the Burnet Institute to explore new antiviral applications for its lead drugs, targeting measles, chikungunya, and Ross River virus. This collaboration leverages existing data and government funding to enhance the company’s clinical pipeline without major capital outlay.

A new clinical study from Sichuan University confirms that TruScreen’s AI-enabled cervical cancer screening combined with high-risk HPV testing outperforms traditional cytology methods, reinforcing its global potential.

Pro Medicus Limited’s U.S. subsidiary has locked in two significant 5-year contract renewals worth a combined minimum of A$40 million, reinforcing its position in the competitive medical imaging market.

Spenda Limited has successfully raised $1.4 million through a private placement, supported by both new and existing sophisticated investors, including key directors. The funds will fuel the company’s commercialisation efforts and strengthen its working capital position.